184 related articles for article (PubMed ID: 28895206)
1. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.
Shah N; Cornelison AM; Saliba R; Ahmed S; Nieto YL; Bashir Q; Parmar S; Hosing C; Popat U; Shpall EJ; Champlin RE; Qazilbash M
Eur J Haematol; 2017 Dec; 99(6):532-535. PubMed ID: 28895206
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
3. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
[TBL] [Abstract][Full Text] [Related]
4. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
5. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings.
Dunavin N; Mau LW; Meyer CL; Divine C; Abdallah AO; Leppke S; D'Souza A; Denzen E; Saber W; Burns LJ; Ganguly S
Biol Blood Marrow Transplant; 2020 Apr; 26(4):805-813. PubMed ID: 31917269
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
[TBL] [Abstract][Full Text] [Related]
9. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
10. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
Kawamura K; Ikeda T; Hagiwara S; Mori T; Shinagawa A; Nishiwaki K; Ohashi K; Kubonishi S; Fukuda T; Ito T; Tomita N; Ichinohe T; Kato K; Morishima Y; Atsuta Y; Sunami K; Kanda Y
Leuk Lymphoma; 2016 Sep; 57(9):2077-83. PubMed ID: 26961137
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
13. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
15. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
16. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Kharfan-Dabaja MA; Hamadani M; Reljic T; Nishihori T; Bensinger W; Djulbegovic B; Kumar A
J Hematol Oncol; 2013 Jan; 6():2. PubMed ID: 23289975
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
